Pulmonary veno-occlusive disease in myeloproliferative disorder.

[en] The present study reports a case of biopsy-proven pulmonary veno-occlusive disease as a cause of severe pulmonary hypertension in a patient suffering from a chronic myeloproliferative disorder. The pulmonary disease evolved favourably under treatment with defibrotide, a pro-fibrinolytic medication used in hepatic veno-occlusive disease.

Disciplines :

Hematology

Author, co-author :

Willems, Evelyne ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Canivet, Jean-Luc ; Centre Hospitalier Universitaire de Liège - CHU > Soins intensifs

Ghaye, Benoît ; Centre Hospitalier Universitaire de Liège - CHU > Imagerie médicale

de Leval, Laurence ; Centre Hospitalier Universitaire de Liège - CHU > Anatomie pathologique

Radermecker, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie cardio-vasculaire

Preiser, Jean-Charles ; Centre Hospitalier Universitaire de Liège - CHU > Soins intensifs

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

Pulmonary veno-occlusive disease in myeloproliferative disorder.

Publication date :

2009

Journal title :

European Respiratory Journal

ISSN :

0903-1936

eISSN :

1399-3003

Publisher :

European Respiratory Society, Lausanne, Switzerland

Volume :

Issue :

Pages :

213-216

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 10 February 2009

Statistics

Number of views

160 (28 by ULiège)

Number of downloads

213 (12 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-1973.
Holcomb BW Jr, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118: 1671-1679.
Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120: 801-808.
Reisner SA, Rinkevich D, Markiewicz W, Tatarsky I, Brenner B. Cardiac involvement in patients with myeloproliferative disorders. Am J Med 1992; 93: 498-504.
Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 1997; 23: 379-383.
Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928.
Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003; 17: 63-70.
Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008; 41: 229-237.
Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003; 17: 1636-1642.
Pescador R, Porta R, Ferro L. An integrated view of the activities of defibrotide. Semin Thromb Hemost 1996; 22: 71-75.